Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aurinia Pharmaceuticals ( (AUPH) ) has shared an announcement.
Aurinia Pharmaceuticals reported 2025 revenue of $283.1 million, up 20%, driven by a 25% rise in LUPKYNIS net product sales to $271.3 million and significantly higher profitability supported by tax-related benefits. The company strengthened its balance sheet to $398 million in cash and investments while repurchasing 12.2 million shares, and it forecasts 2026 total revenue of $315 million to $325 million, implying continued double-digit growth in its lupus nephritis franchise.
Management expects 2026 to be a pivotal year as it seeks to further expand LUPKYNIS adoption among lupus nephritis patients and advance aritinercept in multiple autoimmune diseases. Aurinia has already initiated one clinical study of aritinercept and plans to start another in the first half of 2026, positioning the company to diversify beyond its flagship product and potentially broaden its presence in the autoimmune therapeutics market.
The most recent analyst rating on (AUPH) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals’ strong financial performance and positive earnings call are the most significant factors driving the stock’s score. The company’s robust revenue growth, profitability improvements, and promising clinical developments are key strengths. However, technical indicators suggest the stock may be overbought, and its high P/E ratio indicates a premium valuation, which could limit further upside.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical needs. Its lead product is LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, and it is also developing aritinercept, a dual BAFF/APRIL inhibitor targeting a broad range of autoimmune indications.
Average Trading Volume: 1,044,377
Technical Sentiment Signal: Buy
Current Market Cap: $1.92B
See more insights into AUPH stock on TipRanks’ Stock Analysis page.